Marinomed Biotech AG
MARI.VI · VIE
6/30/2025 | 3/31/2025 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | – | €6,531 | €1,726 | €738 |
| % Growth | – | 278.3% | 134.1% | – |
| Cost of Goods Sold | – | €0 | €1,038 | €2,245 |
| Gross Profit | – | €0 | €689 | -€1,507 |
| % Margin | – | 0% | 39.9% | -204.4% |
| R&D Expenses | – | €0 | €0 | €1,585 |
| G&A Expenses | – | €0 | €0 | €0 |
| SG&A Expenses | – | €0 | €0 | -€1,192 |
| Sales & Mktg Exp. | – | €0 | €0 | €0 |
| Other Operating Expenses | – | -€15,692 | €2,036 | -€22 |
| Operating Expenses | – | -€15,692 | €2,036 | €370 |
| Operating Income | – | €22,223 | -€1,348 | -€1,878 |
| % Margin | – | 340.3% | -78.1% | -254.6% |
| Other Income/Exp. Net | – | -€22,223 | -€7,356 | -€252 |
| Pre-Tax Income | – | €0 | -€8,703 | -€2,129 |
| Tax Expense | – | €0 | €1 | €1 |
| Net Income | – | €22,122 | -€8,704 | -€2,130 |
| % Margin | – | 338.7% | -504.2% | -288.8% |
| EPS | – | 12.44 | -5.65 | -1.39 |
| % Growth | – | 320.2% | -306.5% | – |
| EPS Diluted | – | 12.44 | -5.65 | -1.39 |
| Weighted Avg Shares Out | – | 1,778 | 1,541 | 1,535 |
| Weighted Avg Shares Out Dil | – | 1,778 | 1,541 | 1,535 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | €0 | €0 | €413 |
| Interest Expense | – | €0 | €7,000 | €664 |
| Depreciation & Amortization | – | €0 | €163 | €165 |
| EBITDA | – | €22,223 | -€1,213 | -€1,301 |
| % Margin | – | 340.3% | -70.3% | -176.4% |